Whalesbook
India's oral rehydration solution (ORS) market has undergone a significant change, driven by regulatory enforcement rather than seasonal demand. New rules have dismantled marketing tactics that used less strict claims, forcing the market to reconsider what qualifies as a real rehydration solution and how it is presented to consumers.
FSSAI Ban Triggers Sharp Market Drop
The Indian ORS market saw a sharp 26% fall in value growth during March. This came after the Food Safety and Standards Authority of India's (FSSAI) strict order, effective from October 2025, prohibiting the use of the "ORS" label on any drink not meeting World Health Organization (WHO) norms. This action removed many sugary and fruit drinks that had used the ORS label, directly affecting sales. PharmaTrac data showed ORS sales value dropped to ₹85 crore in March from ₹115 crore a year earlier. February sales also fell, from ₹111 crore to ₹80 crore. Despite these recent dips, the 12-month moving annual total (MAT) for the ORS market was ₹1,128 crore, an 8% decrease, contrasting with a 13% CAGR recorded over the previous five years.
Competition Intensifies as New Players Rise
The regulatory action has impacted established market leaders. FDC Limited, whose Electral brand historically held over 50% of the ORS market, saw a 7% decline in its MAT sales. This shows that even major players can be affected by regulatory changes when their marketing strategies are challenged. While pharmaceutical companies have traditionally led the ORS market, they now face competition from Fast-Moving Consumer Goods (FMCG) giants like Hindustan Unilever (with Liquid IV) and Reliance Consumer Products Ltd (with RasKik Gluco Energy), who are introducing health-focused products. Cipla's Prolyte ORS, promoted as a low-calorie, WHO-recommended option, has grown substantially, expanding five-fold in three years and gaining market share. This indicates a growing demand for scientifically approved, healthier hydration choices, intensifying competition and challenging FDC's long-standing leadership.
Marketing Missteps Exposed by Regulatory Action
The significant sales decline highlights a key weakness: relying too much on marketing that used medical terms without strict adherence to standards. For years, a campaign led by Dr. Sivaranjani Santosh exposed how sugary drinks were marketed as ORS, posing public health risks, especially to children. The FSSAI's intervention, supported by directives in late 2025, explicitly canceled previous allowances for the ORS label with disclaimers. This suggests that much of the market's value growth was built on a base that couldn't pass regulatory checks. The withdrawal of brands not meeting WHO's composition norms, which require Central Drugs Standard Control Organization (CDSCO) approval for genuine ORS, damages consumer trust in those previously seen as medically sound. This regulatory clean-up may lead to greater consumer skepticism, demanding more transparency and real health benefits. This could favor brands already committed to medical standards or force others into costly product reforms.
Market Faces New Era of Compliance
As India's Over-The-Counter (OTC) healthcare market grows, projected to reach USD 11.62 billion by 2026 with a 13% CAGR, the ORS segment is set for a structural shift. FDC, with a market capitalization of approximately ₹5,900 crore and a P/E ratio around 27.4x as of April 2026, must adapt. Analyst sentiment is mixed, with some recommending "Strong Buy" and others noting past poor sales growth. However, the company's market leadership in ORS and diverse product portfolio, including Zifi and Enerzal, offer a solid foundation. The future success of Electral and similar products will depend on their alignment with genuine WHO-recommended ORS standards and possibly on creating distinct product lines for the growing demand for specialized, functional beverages, similar to Cipla's Prolyte. Companies must now focus on strong scientific validation and clear, compliant communication to rebuild and maintain consumer trust in India's evolving health and wellness sector.